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Abstract
BACKGROUND: The epidemiology of pneumonia has likely evolved in recent years, reflecting 
an aging population, changes in population immunity, and socioeconomic disparities.
METHODS: Using the National (Nationwide) Inpatient Sample, estimated numbers and rates of 
pneumonia-associated hospitalizations for 2001–2014 were calculated. A pneumonia-associated 
hospitalization was defined as one in which the discharge record listed a principal diagnosis of 
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pneumonia or a secondary diagnosis of pneumonia if the principal diagnosis was respiratory 
failure or sepsis.
RESULTS: There were an estimated 20,361,181 (SE, 95,601) pneumonia-associated 
hospitalizations in the United States during 2001–2014 (average annual age-adjusted pneumonia- 
associated hospitalization rate of 464.8 per 100,000 population [95% CI, 462.5–467.1]). The 
average annual age-adjusted pneumonia-associated hospitalization rate decreased over the study 
period (P < .0001). In-hospital death occurred in 7.4% (SE, 0.03) of pneumonia-associated 
hospitalizations. Non-Hispanic American Indian/Alaskan Natives and non- Hispanic blacks had 
the highest average annual age-adjusted rates of pneumonia-associated hospitalization of all race/
ethnicities at 439.2 (95% CI, 415.9–462.5) and 438.6 (95% CI, 432.5–444.7) per 100,000 
population, respectively. During 2001–2014, the proportion of pneumonia-associated 
hospitalizations colisting an immunocompromising condition increased from 18.7% (SE, 0.2) in 
2001 to 29.9% (SE, 0.2) in 2014. Total charges for pneumonia-associated hospitalizations in 2014 
were over $84 billion.
CONCLUSIONS: Pneumonia is a major cause of morbidity and mortality in the United States. 
Differences in rates and outcomes of pneumonia-associated hospitalizations between 
sociodemographic groups warrant further investigation. The immunocompromised population has 
emerged as a group experiencing a disproportionate burden of pneumonia-associated 
hospitalizations.
Keywords
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Together, pneumonia and influenza rank as the eighth leading cause of death in the United 
States.1 While a pathogen is not identified even after extensive diagnostic evaluation in the 
majority of cases, influenza virus is known to be an important contributor to pneumonia.2,3
Factors such as an aging population, changes in population immunity (such as through 
vaccination and immunosuppressive comorbidities), and persisting socioeconomic 
disparities might be contributing to a shift in the national burden of pneumonia.4,5 While 
pneumonia disproportionately affects older adults, the mortality rate from pneumonia among 
older adults is declining.6–9 Among children, the very young face the greatest burden of 
pneumonia, though the introduction of the pneumococcal vaccine (eg, the 7-valent 
pneumococcal conjugate vaccine [PCV7] in 2000) has had an impact.10–12 People who are 
immunocompromised are at increased risk of pneumonia, but the national burden of 
pneumonia- associated hospitalizations among the immunocompromised has not been fully 
characterized.13–18 Finally, disparities have been noted in pneumonia death rates by race/
ethnicity.19
To characterize the national burden of pneumonia after the introduction of PCV7, we 
analyzed hospital discharge data for pneumonia during 2001–2014.
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Materials and Methods
Data Source
We used the National (Nationwide) Inpatient Sample (NIS) to retrospectively analyze 
hospital discharge data with a diagnosis of pneumonia for the general US population during 
2001–2014.20 The NIS is a nationally representative database of hospitalizations and is the 
largest all-payer inpatient database in the United States. The full NIS includes > 7 million 
unweighted hospitalizations per year. For each discharge record in the NIS, we pulled up to 
15 diagnoses (principal diagnosis plus 14 secondary diagnoses) that were coded on the basis 
of the International Classification of Diseases, Ninth Revision, Clinical Modification 
(ICD-9-CM).
Study Approval
Use of the NIS specifically prohibits identification of individual patients. This investigation 
was determined by the Centers for Disease Control and Prevention and the New York City 
Department of Health and Mental Hygiene to be nonhuman subject research.
Definitions
We defined a pneumonia-associated hospitalization as a hospitalization with a principal 
diagnosis of pneumonia (ICD-9-CM code 480–486, 487.0, 488.01, 488.11, or 488.81), or a 
secondary diagnosis of pneumonia if the principal diagnosis was respiratory failure (ICD-9- 
CM code 518.81, 518.82, 518.84, or 799.1) or sepsis (ICD-9-CM code 038, 785.52, 995.91, 
or 995.92).7 Of note, ICD-9-CM codes 487.0, 488.01, 488.11, and 488.81 relate to 
“influenza with pneumonia”; we did not include other “influenza” ICD-9-CM codes within 
the 487 and 488 categories because they did not specify an associated “pneumonia.” 
Together, these four ICD-9-CM codes accounted for 1.1% (SE, 0.01) of all pneumonia-
associated hospitalizations during the study period.
A pneumonia episode was considered to be of unspecified etiology if the discharge record 
contained a principal diagnosis of “bronchopneumonia, organism unspecified” or 
“pneumonia, organism unspecified” (ICD-9-CM codes 485 and 486, respectively); all other 
pneumonia-associated hospitalizations that listed a pneumonia diagnostic code as the 
principal diagnosis other than ICD-9-CM codes 485 or 486 were considered to have a 
specified etiology.
Pneumonia-associated hospitalizations of persons who were immunocompromised were 
identified if an ICD-9-CM code for an immunocompromising condition was colisted on the 
discharge record21 (e-Table 1).
Data Analysis
Estimates and standard errors of the number of pneumonia-associated hospitalizations were 
calculated from the NIS, using the Healthcare Cost and Utilization Project weighting 
methodology.20,22,23 The unit of analysis was a hospitalization; NIS data do not have person 
identifiers, and therefore any repeat pneumonia-associated hospitalizations of the same 
patient were included.
Hayes et al. Page 3
Chest. Author manuscript; available in PMC 2019 June 10.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Average annual and annual hospitalization rates with 95% CIs were expressed as the 
weighted number of hospitalizations per 100,000 persons of the corresponding population. 
Age-adjusted rates with 95% CIs were calculated by the direct method, with the 2000 
projected US population as the standard; crude weights were calculated for specific age 
groups and income quartiles. Denominators were taken from the National Center for Health 
Statistics annual bridged race population estimates for the study period.24 We used Poisson 
regression to calculate rate ratios and 95% CIs, and test for trends over time. A P value < .05 
was considered statistically significant.
Pneumonia-associated hospitalization records were examined by sex, age, race/ethnicity, 
region, ZIP code income quartile, month of admission, in-hospital death, colisting of 
immunocompromising conditions, and charges (in 2014 US dollars). Hospital charges 
reflected the amount that the medical facility billed for the hospitalization, but did not 
include professional (physician) fees. Income quartiles by ZIP code are consistent for the 
years 20032014 and were used in this study. To examine trends, we compared average 
annual rates for 2001–2003 to 2012–2014. Some discharge records had missing information 
on sex (0.1% [SE, < 0.01]), age (0.03% [SE, < 0.01]), race/ethnicity (19.0% [SE, 0.4]), and 
charges (1.7% [SE, 0.1]); adjustments were not made for missing data.
All analyses were generated with SAS, version 9.3. Weighted estimates and corresponding 
SEs were calculated with SUDAAN to account for the NIS sampling design.
Results
During 2001–2014, there were 463,384,760 (SE, 2,162,304) hospitalizations in the United 
States, including 20,361,181 (SE, 95,601) pneumonia-associated hospitalizations (4.4% [SE, 
0.01]) (Table 1). This corresponds to an average of 1,454,370 (SE, 6,829) pneumonia-
associated hospitalizations per year or an average annual age-adjusted pneumonia-associated 
hospitalization rate of 464.8 per 100,000 population (95% CI, 462.5–467.1). During 2001–
2014, the annual age-adjusted rate of pneumonia-associated hospitalizations decreased (P < .
0001) (Fig 1).
The majority of pneumonia-associated hospitalizations listed a pneumonia principal 
diagnosis (76.8% [SE, 0.1] of pneumonia-associated hospitalizations), corresponding to an 
average annual age-adjusted hospitalization rate of 358.3 per 100,000 population (95% CI, 
356.4–360.1) (Table 2). The remaining pneumonia-associated hospitalizations listed a 
respiratory failure or sepsis principal diagnosis, corresponding to an average annual age-
adjusted hospitalization rate of 106.6 per 100,000 population (95% CI, 105.8–107.3). The 
rate of pneumonia- associated hospitalizations with a pneumonia principal diagnosis 
decreased over the study period (P < .0001) while the rate for those with a respiratory failure 
or sepsis principal diagnosis increased (P < .0001) (Fig 1).
The majority of pneumonia-associated hospitalizations with a pneumonia principal diagnosis 
were of unspecified pneumonia etiology (Table 2). The most common specified etiology 
among pneumonia-associated hospitalizations listing a pneumonia principal diagnosis was 
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nonpneumococcal bacteria (ICD-9-CM code 482), accounting for 7.6% (SE, 0.1) of overall 
pneumonia-associated hospitalizations.
In-Hospital Death
In-hospital death occurred in 7.4% (SE, 0.03) of pneumonia-associated hospitalizations 
(Table 1). From 2001–2003 to 2012–2014, there was no significant change in the proportion 
of pneumonia-associated hospitalizations with in-hospital death. In-hospital death occurred 
in 3.9% (SE, 0.02) of pneumonia-associated hospitalizations listing a pneumonia principal 
diagnosis, vs 19.0% (SE, 0.1) of pneumonia-associated hospitalizations listing a respiratory 
failure or sepsis principal diagnosis.
Hospitalizations by Sex, Age Group, Race/ Ethnicity, Region, and Income Quartile
Male subjects had a higher average annual age-adjusted rate of pneumonia-associated 
hospitalization than female subjects (Table 1). Average annual age-adjusted rates of 
hospitalization decreased for both male and female subjects from 2001–2003 to 2012–2014 
(Table 3).
The average annual rate of pneumonia-associated hospitalization was highest in those aged < 
1 year and those aged ≥ 65 years (Table 1). The proportion of pneumonia-associated 
hospitalizations with in-hospital death was highest among people aged ≥ 65 years. The rate 
of pneumonia-associated hospitalizations decreased from 2001–2003 to 2012–2014 for all 
age groups except for the 20- to 44-year and 45- to 64-year age groups (Table 3).
Non-Hispanic American Indian/Alaskan Natives and non-Hispanic blacks had the highest 
average annual age- adjusted rates of pneumonia-associated hospitalization of all race/
ethnicities; non-Hispanic Asian/Pacific Islanders had the lowest average annual age-adjusted 
rate (Table 1). The proportion of pneumonia-associated hospitalizations with in-hospital 
death was highest among non-Hispanic Asian/Pacific Islanders, whereas it was lowest 
among non-Hispanic American Indian/ Alaskan Natives and Hispanics. Both non-Hispanic 
Asian/Pacific Islanders and Hispanics saw a decrease in the average annual age-adjusted rate 
of pneumonia- associated hospitalizations from 2001–2003 to 2012–2014; the average 
annual age-adjusted rate of pneumonia-associated hospitalization increased among non-
Hispanic whites and non-Hispanic blacks (Table 3).
The South had the highest rate of pneumonia-associated hospitalizations of all regions, 
though in-hospital death occurred more often in the Northeast (Table 1). All regions 
experienced a decrease in the rate of pneumonia-associated hospitalizations from 2001–2003 
to 2012–2014 (Table 3).
The average annual rate of pneumonia-associated hospitalization decreased as income 
quartile increased (Table 1). The proportion of pneumonia-associated hospitalizations with 
in-hospital death increased with increasing income quartile. The mean age at in-hospital 
death was lowest in the lowest income quartile (73.1 years [95% CI, 72.9–73.2]) and highest 
(76.4 years [95% CI, 76.2–76.6]) in the highest income quartile.
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Hospitalizations by Immune Status
During 2001–2014, the proportion of pneumonia-associated hospitalizations colisting an 
immunocompromising condition increased from 18.7% (SE, 0.2) in 2001 to 29.9% (SE, 0.2) 
in 2014 (Fig 2, and e-Figs 1–3). In-hospital death occurred in 10.9% (SE, 0.1) of 
pneumonia-associated hospitalizations colisting an immunocompromising condition 
compared with 6.3% (SE, 0.03) among those not colisting an immunocompromising 
condition (P < .0001).
Seasonality
Age-adjusted pneumonia-associated hospitalization rates were highest from December 
through March (Fig 3A). The proportion of pneumonia-associated hospitalizations with in-
hospital death was highest for those with an admission month of July (8.2% [SE, 0.1]) and 
lowest in March (7.1% [SE, 0.1]), April (7.1% [SE, 0.1]), and May (7.1% [SE, 0.1]) (Fig 
3B).
Charges
Total charges for pneumonia-associated hospitalizations in 2014 were $84,392,702,156 (SE, 
1,285,930,398).
Discussion
This study underscores the large burden of pneumonia-associated hospitalizations in the 
United States, particularly among infants, older adults, those of lower socioeconomic status, 
certain race/ethnicities, and the immunocompromised. On average, approximately 1.5 
million pneumonia-associated hospitalizations occurred per year, resulting in over $84 
billion in charges in 2014.
We focused on a period after the introduction of PCV7, and observed that the average annual 
age-adjusted rate of pneumonia-associated hospitalizations and the proportion with in-
hospital death decreased during the study period. This downward trend, largely driven by a 
downward trend in pneumonia principal diagnoses, may be related to several factors, 
including PCV7 introduction, changes in coding practices, and changes in health-care 
delivery, among others. While these trends are reassuring, the rate of pneumonia-associated 
hospitalizations that involved a principal diagnosis of respiratory failure or sepsis tripled 
from 2001–2003 to 2012–2014. This is consistent with previously reported data, and likely 
reflects a coding bias.7
Consistent with previous studies, infants and adults aged ≥ 65 years experienced higher 
average annual rates of pneumonia-associated hospitalization than other age groups.6,12 
Pneumococcal and influenza vaccination are a primary means of pneumonia prevention 
among these age groups, but the proportion of the population vaccinated for these conditions 
remains below target levels.25,26 Meanwhile, average annual rates of pneumonia-associated 
hospitalization decreased during the study period for all age groups except persons aged 20–
44 and 45–64 years. The reasons for the rise in pneumonia-associated hospitalization rate 
among these particular age groups are unclear.
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Also consistent with previous studies, male subjects experienced higher average annual age-
adjusted pneumonia-associated hospitalization rates than female subjects.27 Several lifestyle, 
behavioral, and socioeconomic factors may play a role in this difference.28 Male subjects 
also had a higher percentage of pneumonia-associated hospitalizations with in-hospital death 
than female subjects. Previous research has shown that differences in mortality persist even 
after adjusting for behavior and comorbidities, and sex-specific immune responses might 
play a role.29
Although inroads have been made in quantifying and elucidating the cause of racial and 
ethnic health disparities in pneumonia, our data show that differences persist.30,31 Consistent 
with previous reports, non- Hispanic blacks had among the highest rates of pneumonia-
associated hospitalization among all race/ ethnicity groups—perhaps due to a higher 
prevalence of underlying pneumonia risk factors such as smoking and certain chronic 
conditions.31–34 Furthermore, we found that non-Hispanic American Indian/Alaskan Natives 
had a high rate of pneumonia-associated hospitalizations compared with other race/
ethnicities.
These data are consistent with other studies that have examined health disparities among 
non-Hispanic American Indian/Alaskan Natives.35,36 Though non-Hispanic whites did not 
have as high a rate of pneumonia-associated hospitalizations compared with other race/
ethnicities, the apparent increase in age-adjusted hospitalization rates over time among this 
demographic and among non-Hispanic blacks is concerning. Differences by race/ethnicity in 
the proportion of pneumonia-associated hospitalizations with in-hospital death (eg, 6.2% in 
Hispanics vs 9.6% in non-Hispanic Asian/Pacific Islanders) were also identified.
The association between income quartile and pneumonia-associated hospitalization rates that 
we found is consistent with data from other investigations.33 Lower income is associated 
with multiple pneumonia risk factors such as smoking, worse access to health care, and 
lower pneumococcal and influenza vaccination rates.25,34,37 There are likely additional 
effects of race/ethnicity and income; however, without population denominators of the 
distribution of race/ethnicity within each of the US income quartiles, we were unable to 
create rates to describe this relationship. Paradoxically, the proportion of pneumonia-
associated hospitalizations with in-hospital death increased with income quartile. We suspect 
that this might be an artifact of age, given that mean age at in-hospital death also increased 
with income quartile.
The proportion of pneumonia-associated hospitalizations listing an ICD-9-CM code for an 
immunocompromising condition almost doubled from 2001 to 2014. Part of our findings 
may be explained by persons with immunocompromising conditions living longer.38,39 
While the data we present highlight the importance of monitoring pneumonia among 
immunocompromised individuals, caution should be taken in their interpretation for multiple 
reasons. First, it is possible that our data related to immune status are subject to some 
unrecognized bias, as the codes we used have not been validated through chart review. 
Furthermore, the median number of secondary diagnoses listed on the discharge record for 
any hospitalization (not just pneumonia-associated hospitalizations) almost doubled from 
3.8 (SE, 0.03) during 2001–2003 to 7.5 (SE, 0.02) during 2012–2014 (P < .05). Thus, there 
Hayes et al. Page 7
Chest. Author manuscript; available in PMC 2019 June 10.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
is likely a bias over time to list secondary diagnoses on the discharge record, and this might 
explain why the proportion of pneumonia- associated hospitalizations colisting an 
immunocompromising condition increased during the study period. Second, some of the 
ICD-9-CM codes we used to identify immunocompromising conditions include a wide 
spectrum of severity in which the early stages of disease might not greatly impair the 
immune system, thus potentially overestimating the proportion of pneumonia-associated 
hospitalizations involving immunocompromised people. Third, chronic kidney disease, a 
condition that can suppress the immune system, was purposely excluded from our analysis 
because additional subdiagnoses were added to the ICD- 9-CM code for this condition in 
2005.40 When we tested the impact of including this ICD-9-CM code in our analysis, we 
observed a dramatic inflation in the proportion of pneumonia-associated hospitalizations 
colisting an immunocompromising condition starting in 2005 (e-Fig 4). Fourth, our data do 
not capture outpatient treatment of pneumonia, and pneumonia in an immunocompetent 
person is more likely to be treated in the outpatient setting41.
Understanding the etiology of pneumonia can help with targeting specific therapies for 
individual patients and with focusing public health interventions, but we found that > 60% of 
pneumonia-associated hospitalizations with a pneumonia principal diagnosis had no 
specified etiology. This is consistent with data from previous studies showing that a 
pneumonia etiology is often not identified even after extensive investigation.2,3
While hospital discharge data are useful for estimating trends in pneumonia-associated 
hospitalizations, there are limitations. The data presented reflect hospitalizations, not 
patients, and a single patient may be hospitalized more than once. As a sizeable proportion 
of patients with pneumonia are treated in the outpatient setting, our study estimates the more 
severe cases. We may have incorrectly estimated disease burden, due to use of nonspecific 
ICD-9-CM codes that included nonpneumonia illnesses and because we do not know the 
accuracy of the diagnoses listed on the discharge record. As administrative data can be 
affected by external factors such as reimbursement policies, the selection and distribution of 
principal and secondary diagnostic codes could be biased.42 However, to overcome a well-
documented selection bias in coding for pneumonia, we chose to define “pneumonia-
associated hospitalizations” as discharge records in which there was either a pneumonia 
principal diagnosis or a pneumonia secondary diagnosis in combination with a principal 
diagnosis of respiratory failure or sepsis.7
In conclusion, pneumonia causes significant morbidity and mortality in the United States. 
Populations such as the very young and older persons have historically faced the greatest 
risk, which is still the case today. Persons who are immunocompromised have emerged as a 
group representing an increasing proportion of pneumonia-associated hospitalizations. 
Understanding the burden of pneumonia-associated hospitalizations can potentially inform 
clinical treatment and public health interventions, and should continue to be monitored.
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Figure 1- 
Annual age-adjusted rates of pneumonia-associated hospitalizations: United States, 2001–
2014.
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Figure 2- 
Proportion of pneumonia-associated hospitalizations colisting an immunocompromising 
condition: United States, 2001–2014.
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Figure 3- 
A, Age-adjusted rate of pneumonia-associated hospitalizations by month of admission: 
United States, 2001–2014. B, Proportion of pneumonia-associated hospitalizations with in-
hospital death by month of admission: United States, 2001–2014
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